• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

National Rosacea Society announces research grants

Barrington, Ill. - The National Rosacea Society (NRS) has awarded funding to four new studies aimed at learning more about the causes and management of rosacea.

Barrington, Ill. - The National Rosacea Society (NRS) has awarded funding to four new studies aimed at learning more about the causes and management of rosacea.

An NRS press statement announced funding for the following studies:

  • $25,000 to Richard Gallo, M.D., chief of the division of dermatology, University of California San Diego, and Kenshi Yamasaki, M.D., of the Veterans Medical Research Foundation, to continue their ongoing research into the role cathelicidins may play in the development of subtype 2 (papulopustular) rosacea.

  • $25,000 to Yolanda Helfrich, M.D., assistant professor of dermatology, University of Michigan, for a study comparing subtype 1 (erythematotelangiectatic) rosacea and photoaging, both of which may include the development of telangiectasia and erythema.

  • $25,000 to Richard Granstein, M.D., chairman of dermatology, Cornell University, and colleagues to continue their research on the role of adenosine triphosphate (ATP) in recruiting inflammatory cells in subtype 2 rosacea.

  • $25,000 to Martin Steinhoff, M.D., of the department of dermatology, University of Muenster, Germany. Dr. Steinhoff will study the role of neuroimmune interactions in the pathophysiology of rosacea.

 

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.